Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Big Is The Dasatinib Drugs Market Today And What Is Its Future Size?

In recent years, there has been a robust growth in the market size of dasatinib drugs. The market is projected to expand from $1.45 billion in 2024 to $1.53 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.8%. The historical development is linked to a rise in cases of chronic myeloid leukemia (CML), expansion in designated cancer therapies, advancements in research on tyrosine kinase inhibitors (TKIS), surge in investment towards oncology research, and an increase in the count of clinical trials.

The market size for dasatinib drugs is projected to witness substantial growth in the coming years, reaching $1.95 billion by 2029 with a compound annual growth rate (CAGR) of 6.3%. This anticipated growth during the forecast period can be traced back to an increase in oncology drug investments, a surge in cases of drug-resistant leukemia, availability of generic dasatinib drugs, an enhanced focus on decreasing chemotherapy side-effects, and improved awareness and early detection of leukemia. The forecast period is also expected to see significant trends such as the adoption of tailor-made medicine, the incorporation of companion diagnostics, the creation of new drug formulations, advancements in combined therapies, and the development of biosimilars.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19023&type=smp

Which Growth Drivers Are Shaping The Dasatinib Drugs Market Outlook?

The escalating occurrence of chronic myeloid leukemia (CML) is anticipated to stimulate the expansion of the dasatinib drug market in the future. CML, a form of cancer that affects the bone marrow and blood, is characterized by an unusual proliferation of white blood cells. The mounting occurrence of chronic myeloid leukemia (CML) can largely be attributed to lifestyle demographics, unhealthy food habits, and growing environmental risk factors. Dasatinib medications play a significant role in treating CML by restricting the activities of BCR-ABL (gene fusion), a tyrosine kinase protein which is generated by the Philadelphia chromosome mutation, leading to the unchecked proliferation of cancerous white blood cells. For example, the American Cancer Society (ACS), a healthcare organization based in the U.S. focused on eradicating cancer, stated in January 2023 that instances of chronic myeloid leukemia (CML) in the United States surged to 8,930, up from 8,860 in 2022. Hence, the escalating incidence of chronic myeloid leukemia (CML) is acting as a driving force for the dasatinib drug market.

Which Segmentation Categories Are Highlighted In The Dasatinib Drugs Market Analysis?

The dasatinib drugs market covered in this report is segmented –

1) By Product Type: Tablets, Oral Suspension, Other Products

2) By Indication: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Other Indications

3) By End User: Hospitals, Specialty Clinics, Home Healthcare

Subsegments:

1) By Tablets: 20 mg Tablets, 50 mg Tablets, 70 mg Tablets, 80 mg Tablets

2) By Oral Suspension: 20 mg Or 5 mL Oral Suspension, 40 mg Or 5 mL Oral Suspension

3) By Other Products: Injectable Formulations, Combination Therapies, Generic Dasatinib Products

Which Market Trends Are Expected To Define The Future Of The Dasatinib Drugs Market?

In a bid to grow their market presence, key businesses in the dasatinib drugs market are prioritizing the creation of generic drugs. These drugs not only increase cost efficiency but also enhance patient accessibility. In the dasatinib market, patients gain access to a cheaper treatment alternative, which promotes competition and reduces their healthcare expenses. For instance, Apotex Corp., a pharmaceutical firm from Canada, launched the first generic variant of Sprycel dasatinib in September 2024 within the U.S. to treat specific leukemia types in adults and children. This economic alternative enhances access to high-quality treatment choices. Its advent signals a major shift towards fostering competition and reducing prices in the dasatinib market.

Which Organizations Are At The Forefront Of The Dasatinib Drugs Market?

Major companies operating in the dasatinib drugs market are Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sandoz Group AG, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, MSN Laboratories Pvt. Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Mylan N.V., Manus Aktteva Biopharma LLP

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/dasatinib-drugs-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Dasatinib Drugs Market?

North America was the largest region in the dasatinib drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dasatinib drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=19023&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model